Recombinant rabies virus as potential live-viral vaccines for HIV-1. - Wikidata - wikimedia - TriplyDB

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

http://www.wikidata.org/entity/Q35115861

about

Rabies virus glycoprotein as a carrier for anthrax protective antigen Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.Design and generation of recombinant rabies virus vectors.Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic Immunogenicity of cytopathic and noncytopathic viral vectors Rhabdovirus-based vaccine platforms against henipaviruses Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Nonsegmented negative-strand viruses as vaccine vectors.New rabies virus variants for monitoring and manipulating activity and gene expression in defined neural circuits Rabies virus nucleoprotein as a carrier for foreign antigens.A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection.Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity.Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene Reinvestigating the role of IgM in rabies virus postexposure vaccination.Rabies virus stimulates nitric oxide production and CXC chemokine ligand 10 expression in macrophages through activation of extracellular signal-regulated kinases 1 and 2.ICAM-1-based rabies virus vaccine shows increased infection and activation of primary murine B cells in vitro and enhanced antibody titers in-vivo.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.Probiotics: multifarious oral vaccine against infectious traumas.RNA-based viral vectors.Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein.Reverse genetics in high throughput: rapid generation of complete negative strand RNA virus cDNA clones and recombinant viruses thereof.APRIL:TACI axis is dispensable for the immune response to rabies vaccination.Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A.McCoy cell line as a possible model containing CD4+ receptors for the study of HIV-1 replication.Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

P2860

Q28391261-BBD66F9C-4DDC-4658-8868-D1A5FBBEC5BD Q31016943-C5B54BE8-A4A2-41BE-ADAB-002F56D38519 Q33641074-77A9E6D1-93EB-4B0D-B94D-46354176616F Q33839981-6D5CADCE-044E-4A73-9A4C-564C22C5EFFF Q33848911-ABE7F946-4BCE-462B-BC1B-B0743DAFC390 Q33854615-B72FF15B-D5F2-4CBA-BD5F-B2C3C78C9A79 Q34327387-DBADE40F-1655-43A6-BBD2-15BC4DFCD8F6 Q34334320-37692026-BF3E-4878-9E75-4C2AD525EF34 Q34338054-53A25B6E-5B40-41AE-90E7-FFA8AE760C78 Q34461764-F124983F-4CD0-4763-8BAA-AAEDBCD9FB91 Q34716855-2B63FF75-FB2D-40CD-859A-924825A57D13 Q34992537-230E106A-3472-4A09-A0A2-E916889A83FD Q34999206-E43B1AED-7E07-4F59-B7CD-E57EE622BBEA Q35043107-770760F8-7A53-4FC8-8DB7-58BDC9573459 Q35139219-3FB0917E-6F96-4608-BC88-BA74D159DAF2 Q35293727-E71C9A7D-EFE3-4DD7-99CB-503971D21989 Q35320069-74FC642C-1B2F-4640-92E7-6AB2507F1981 Q35853085-C625F264-4AE1-47EB-8042-365B475E3ACB Q36043269-127920F7-5312-4BD4-BBA6-0EE12D132674 Q36073443-5AE29149-FFE8-4BBE-AD3F-288F72490B33 Q36294739-00561FD2-9580-431A-A61E-7910D728899F Q36363223-0F0AC1A3-362E-412E-A955-D3FD36498742 Q36474235-17450513-1369-47E9-8FBF-7E17F0E2C5C4 Q36898934-BCFCB3DE-E5DE-499F-9A87-36409881A2CB Q37059997-886CDBA2-4997-412B-A9C4-9F26D06DEC6B Q37068893-3C171748-FCE5-4336-8630-670055122748 Q37123389-1092B5D4-3A04-4465-A0E4-C53F391EA5A4 Q37348438-F6023396-E473-4016-ACA3-2EBB575F4811 Q37529574-82E4BEE1-009C-4899-B1BB-CA8DF15CB6AF Q37560824-DD563A0D-B2E4-4491-B418-A3417A021F39 Q37681016-48560233-7F2D-4A31-B3D9-D584275EF71C Q38266413-BD556B2A-01BF-463C-B6EA-E1ADFAC0B30B Q38295138-6A42958C-2FBC-4FF6-8F19-FF272CDA5C73 Q38780584-B86A8E8F-148D-4B20-9FD8-B6E276EA9EEB Q40158110-4EE153B3-DEE1-46B4-85C5-487DD4659236 Q40349772-9E0C6B37-8E6F-4842-80C6-2A25DF2389D9 Q40355293-21D32A2E-8D7A-48FA-8658-CF0512C9438D Q40539397-4A79FB3F-069D-4407-A776-E4FBE201B9E4 Q40632696-6F3E204F-DF2E-46B6-9BD1-64C991560E41 Q41217724-C39371B2-BE38-412E-9400-D0C84A830AFA

P2860

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

http://www.wikidata.org/entity/Q35115861

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@ast

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@en

type

label

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@ast

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@en

prefLabel

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@ast

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@en

P1433

Q35115861-76018CA3-A591-4E32-8955-6F8397DE664E

P1476

Q35115861-8FB25418-91D7-4E0C-9A26-39255CAFC814

P2093

Q35115861-261DC204-4054-4EFC-8416-7A590547F8CB

Q35115861-4B91E224-3F11-4FDD-A12F-4CDEFBB567B4

Q35115861-7748900B-5B64-40B4-86A4-6530A148B4EC

Q35115861-7A98F9E0-B916-4A5F-B3D9-CDBFEE0688F1

Q35115861-85CD83F9-477F-46FE-9CA4-73E044EA31CF

Q35115861-967057A9-B8D1-46E1-B3EC-EF8ACE3E5A4E

P2860

Q35115861-08E61722-9C64-4DAF-8185-16A335810AC7

Q35115861-092D6779-76E8-4EE3-B679-F7134FA22930

Q35115861-0B52E5D2-A455-40F0-BE25-8E7BEDC0950A

Q35115861-122FBC72-E08E-4E32-AE2B-777674788E14

Q35115861-14275AF4-A221-4002-8492-AEC8B1C642B6

Q35115861-1D29D2B7-2AA7-46C9-8E6D-0B1BB01E0C9A

Q35115861-226745D2-0234-4FCA-B11D-FF9130ED06A2

Q35115861-2325B1B1-2FE4-4642-9E90-CE02A946F79C

Q35115861-26560DDA-B98F-4226-9E31-64D754E90D78

Q35115861-3479589F-8F16-4522-9609-EC5983F8B6DE

P304

Q35115861-32B3A46E-C75D-4796-B3B5-EDC00BCDC57C

P31

Q35115861-2B21BCFD-3124-4FCA-AABB-69929201C916

P356

Q35115861-76BE6BE0-CE2E-4F33-B1F8-1A42AE9C272E

P407

Q35115861-9712878B-3FC8-4E48-966A-5863E76907CD

P433

Q35115861-B6973ACC-FEB1-4D88-A17A-582D7F1AC4C6

P478

Q35115861-249B4A00-5F80-49F6-A992-31244DD0FE7B

P577

Q35115861-F9199BDB-0E10-402C-9560-62C72B464A6B

P698

Q35115861-5F647820-1386-430A-9F83-1DD783ED6536

P921

Q35115861-BF988B12-6347-4521-9E02-599DCF87DE7C

P932

Q35115861-C0D9E0A4-8767-49EE-A70D-E6F7270D24F7

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

@en

P2093

B Dietzschold

http://www.w3.org/2001/XMLSchema#string

C A Siler

http://www.w3.org/2001/XMLSchema#string

H D Foley

http://www.w3.org/2001/XMLSchema#string

J P McGettigan

http://www.w3.org/2001/XMLSchema#string

M J Schnell

http://www.w3.org/2001/XMLSchema#string

R J Pomerantz

http://www.w3.org/2001/XMLSchema#string

P2860

Folding and assembly of viral membrane proteins.

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

The use of combination antiretroviral therapy in HIV-infected patients.

HIV disease treatment in the era of HAART.

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza

Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.

P304

3544-3549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.97.7.3544

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10706640

http://www.w3.org/2001/XMLSchema#string

P921

P932

16276

http://www.w3.org/2001/XMLSchema#string